John McGee

John McGee is a Scientific Co-Founder and Senior Vice President of Platform Technology at Parabilis Medicines, where he and his team develop experimental platforms to discover and optimize helically constrained (Helicon) peptides for undruggable target proteins. Prior to joining Parabilis, John was a postdoctoral research fellow at Harvard University, where he worked in the laboratory of Dr. Greg Verdine and performed foundational work on both the de novo screening and multiplexing platforms that now form the core of Parabilis Medicines’ experimental discovery engine. John received a B.S. in chemistry from Stanford University, where he studied with Dr. Eric Kool, and a Ph.D. in biochemistry from Harvard University, where he studied with Dr. Greg Verdine